Bicara Therapeutics is a clinical-stage biopharmaceutical company developing bifunctional antibody therapies for solid tumors. Its lead program, ficerafusp alfa, combines an EGFR-directed monoclonal antibody with a TGF-β-targeting component intended to both block tumor growth signaling and modulate the tumor microenvironment. The company is based in Boston and focuses on targeted oncology rather than commercial product sales at this stage.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -36.9 | — |
| Q2 2025 | 0 | — | -27.4 | — |
| Q3 2025 | 0 | — | -36.3 | — |
| Q4 2025 | 0 | — | -37.4 | — |
| Q1 2026 | 0 | — | -56.2 | — |
| Q2 2026 | 0 | — | -55.4 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: ZoomInfo Technologies Inc. (GTM), JetBlue Airways Corporation (JBLU), National Healthcare Properties, Inc. (NHP), Amphastar Pharmaceuticals, Inc. (AMPH), Willdan Group, Inc. (WLDN), Hotel101 Global Holdings Corp. (HBNB)